Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cytokinetics, Inc. (NASDAQ: CYTK).

Full DD Report for CYTK

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYTK)

Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16 th Annual Morgan Stanley Global Healthcare Conference on Wednes...
Source: GlobeNewswire
Date: September, 05 2018 16:00
Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intended to suppor...
Source: GlobeNewswire
Date: August, 28 2018 08:30
Market Trends Toward New Normal in US Foods Holding, Limelight Networks, Ladenburg Thalmann Financial Services, MPLX LP, Cytokinetics, and FuelCell Energy - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US Foods Holding Corp. (NYSE:USFD), Limelight Networks, Inc. (NASDAQ:LLNW...
Source: GlobeNewswire
Date: August, 01 2018 08:10
Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q2 2018 Results - Earnings Call Transcript
Cytokinetics, Inc. (CYTK) Q2 2018 Results Earnings Conference Call July 26, 2018, 04:30 PM ET Executives Diane Weiser - VP, Corporate Communications, and IR Robert Blum - President and CEO Fady Malik - EVP, Research and Development Andrew Wolff - SVP and CMO Peter Roddy - SVP...
Source: SeekingAlpha
Date: July, 26 2018 21:34
Cytokinetics EPS in-line, beats on revenue
Cytokinetics (NASDAQ: CYTK ): Q2 EPS of -$0.51 in-line. More news on: Cytokinetics, Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 26 2018 16:01
Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results
Phase 2 Study of Reldesemtiv in Patients with SMA  Showed Potentially Clinically Meaningful Effects  on Six Minute Walk Distance and Maximal Expiratory Pressure Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3 Finalizing Prepara...
Source: GlobeNewswire
Date: July, 26 2018 16:00
Cytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will hos...
Source: GlobeNewswire
Date: July, 12 2018 16:00
Midday Gainers / Losers (06/18/2018)
Gainers:  GEVO +236% . OTCPK:LFIN +48% . PTCT +26% . OBSV +26% . ARWR +23% . RCII +22% . VSTM +22% . CBPO +22% . QTNT +19% . EGC +19% . More news on: Gevo, Inc., LongFin Corp.A, PTC Therapeutics, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: June, 18 2018 12:49
Cytokinetics down 15% as mid-stage data on SMA drug reldesemtiv fails to excite investors
Thinly traded Cytokinetics ( CYTK -15.2% ) slumps on almost triple normal volume, albeit on turnover of only 835K shares, in response to its announcement of Phase 2 proof-of-concept data on reldesemtiv in patients with spinal muscular atrophy (SMA). The results were presented at the Annu...
Source: SeekingAlpha
Date: June, 18 2018 12:40
Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 25: Market conditions continue with high volatility. The positive momentum gauge continues with another full week in yellow (medium) moving from a value of 60 at the end of the prior week down to a value of 44 this week. The all time low for the posit...
Source: SeekingAlpha
Date: June, 18 2018 01:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-177.687.267.737.21221,136
2018-12-147.837.708.107.68323,048
2018-12-138.117.918.217.82251,636
2018-12-128.068.008.187.96149,326
2018-12-117.907.968.137.75230,804

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-177,90628,57727.6656Cover
2018-12-14107,697122,59087.8514Short
2018-12-1316,86639,10143.1344Short
2018-12-122,42812,92418.7868Cover
2018-12-1155,08962,61187.9861Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYTK.


About Cytokinetics, Inc. (NASDAQ: CYTK)

Logo for Cytokinetics, Inc. (NASDAQ: CYTK)

Not available

 

Contact Information

 

 

Current Management

  • James H. Sabry / President, CEO

Current Share Structure

  • Market Cap: $499,575,045 - 05/15/2018
  • Issue and Outstanding: 54,008,113 - 02/23/2018

 


Recent Filings from (NASDAQ: CYTK)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 29 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CYTK)

Daily Technical Chart for (NASDAQ: CYTK)


Stay tuned for daily updates and more on (NASDAQ: CYTK)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYTK)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYTK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CYTK and does not buy, sell, or trade any shares of CYTK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/